ChemotherapyFDA-approvedFirst-line
FOLFIRINOX
How it works
FOLFIRINOX is a combination of four chemotherapy drugs (fluorouracil, leucovorin, irinotecan, and oxaliplatin) that work together to kill cancer cells.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Studies show that FOLFIRINOX can improve overall survival in patients with pancreatic cancer, with a median overall survival of approximately 11.1 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Folfirinox and Pembrolizumab for Resectable Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| FOLFIRINOX Chemotherapy for Rectal Cancer with Liver Metastases | Colorectal Cancer | preclinical | — | Source → |
| Testing Narmafotinib in Combination with FOLFIRINOX for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Untreated Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Pegcetacoplan with FOLFIRINOX for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| FOLFIRINOX Chemotherapy for Advanced Pancreatic Cancer: Balancing Benefits and Harms | Pancreatic Cancer | phase-2 | Amongst the 66 patients who completed ≥ 4 cycles, 52 (79%) achieved disease control at FOLFIRINOX completion. | Source → |
| Germline Mutations Affect Pancreatic Cancer Treatment | Pancreatic Cancer | observational | Median progression-free survival was significantly longer in germline-positive patients (10.6 months) compared to germline-negative patients (5.3 months). | Source → |
| Combining Salmonella-IL2 with Chemotherapy for Stage IV Pancreatic Cancer | Pancreatic Cancer | phase-2 | Those patients who received more than five doses of Salmonella-IL2 with FOLFIRINOX had a median progression-free survival of 15 months and a median overall survival of 20.3 months. | Source → |
| Pancreatic Cancer Study Compares First-Line Treatments | Pancreatic Cancer | observational | Median OS was 14.5 months with FFX, 12.4 months with GN, 7.9 months with Gem, and 9.2 months with others. | Source → |
| Triweekly FOLFIRINOX Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The median overall survival was 14.2 months, and the median progression-free survival was 6.7 months. | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Combining CT Scans and Blood Tests to Predict Pancreatic Cancer Outcomes | Pancreatic Cancer | observational | Patients with progressive disease or increased CA 19-9 levels had a median overall survival of 14.3 months. | Source → |
| Pancreatic Cancer Study Finds New Way to Predict Treatment Outcomes | Pancreatic Cancer | observational | Patients with KRAS wild-type tumors had a median overall survival of 17.7 months, compared to 7.8 months for those with KRAS mutant tumors. | Source → |
| FOLFIRINOX Chemotherapy Toxicity Predictors in Pancreatic Cancer Patients | Pancreatic Cancer | observational | — | Source → |
| Induction Chemotherapy for Rectal Cancer with Synchronous Metastases | Colorectal Cancer | phase-3 | Triplet induction was associated with 80% of objective response and 92% of disease control. | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Pancreatic Cancer Treatment Comparison in Morocco | Pancreatic Cancer | observational | The median overall survival was 6 months for patients treated with Folfirinox versus 3 months for those treated with Gemcitabine. | Source → |
| Neoadjuvant Chemotherapy Response in Pancreatic Cancer | Pancreatic Cancer | observational | The 3-year overall survival rate was higher for biochemical responders (71.0%) than for radiology-only responders (53.6%) or non-responders (33.1%). | Source → |
| FOLFIRINOX Chemotherapy Affects Immune System in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Smoking May Reduce Effectiveness of Cancer Treatment for Pancreatic Cancer Patients | Pancreatic Cancer | observational | Adjusted median OS in NAT patients with FOLFIRINOX was not reached for never and former smokers, compared to 26.2 months in active smokers. | Source → |
| New Biomarker Predicts Benefit from FOLFIRINOX in Pancreatic Cancer | Pancreatic Cancer | phase-2 | HRDsig was predictive of 1L FOLFIRINOX chemotherapy benefit with doubled OS relative to gemcitabine and paclitaxel (GP) (rwOS aHR 0.37 [0.22-0.62]) | Source → |
| Chemotherapy Helps Some Pancreatic Cancer Patients Undergo Surgery | Pancreatic Cancer | observational | The median survival time was 39.2 months for patients who had surgery, compared to 16 months for those who did not. | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The adjusted difference in median overall survival was 3.2 months (95% CI, 1.1-7.4) for FOLFIRINOX compared to gemcitabine plus nab-paclitaxel. | Source → |
| Elderly Patients with Pancreatic Cancer May Benefit from Modified FOLFIRINOX Treatment | Pancreatic Cancer | observational | The median overall survival was 14.4 months in elderly patients and 13.9 months in young patients. | Source → |
| Comparing Chemotherapy Regimens for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | The overall response rate was significantly higher in the FFX group (50.0%) than in the Gem (28.2%) and Gem-Cis (27.5%) groups. | Source → |
| New Scoring System Helps Predict Outcomes for Pancreatic Cancer Patients | Pancreatic Cancer | observational | The median overall survival of patients with a score from 0 to 2 was significantly shorter than that of patients with a score from 3 to 5 (22.1 months vs. 53.2 months, P < 0.001). | Source → |
| New Insights into Pancreatic Cancer Treatment | Pancreatic Cancer | review | — | Source → |
| Woman with pancreatic cancer and genetic mutation responds well to chemotherapy | Pancreatic Cancer | observational | — | Source → |
| FOLFIRINOX as Second-Line Treatment for Pancreatic Cancer | Pancreatic Cancer | meta-analysis | FOLFIRINOX had a significantly longer progression-free survival (PFS) (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.52, 0.89) and overall survival (OS) (HR 0.71, 95% CI 0.59, 0.86); and a significantly better objective response rate (ORR) (HR 0.43, 95% CI 0.23, 0.80) and disease control rate (DCR) (HR 0.71, 95% CI 0.58, 0.88). | Source → |
| Chemotherapy Effectiveness in Older Adults with Advanced Pancreatic Cancer | Pancreatic Cancer | observational | FOLFIRINOX was associated with improved radiologic response (P=0.05) and OS (P=0.035). | Source → |
| PDL1/PD-1 Inhibitors Compared to FOLFIRINOX for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-3 | The rate of adverse reactions was lower in 10.3% of patients in the observation group than in 25.8% of patients in the comparison group. | Source → |
| FOLFIRINOX Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | observational | Median overall survival in resected patients was 36 months. | Source → |
| Frozen Section Analysis of Lymph Nodes May Not Be as Important After Cancer Treatment | Pancreatic Cancer | observational | — | Source → |
| Conversion Surgery May Improve Survival in Pancreatic Cancer Patients | Pancreatic Cancer | observational | The median survival was significantly longer in the resection group than in the non-resection group (56 vs 21 months, P < .001). | Source → |
| FOLFIRINOX Therapy Boosts Immune Cells in Pancreatic Cancer Patients | Pancreatic Cancer | lab-study | — | Source → |
| Lab-Grown Tumors Reveal Resistance to Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Second-Line Chemotherapy for Pancreatic Cancer: New Options Compared | Pancreatic Cancer | phase-3 | The objective response rate was 15% in the mFOLFIRINOX group, compared to 2% in the S-1 group. | Source → |
| FOLFIRINOX Dosage for Pancreatic Cancer Patients with UGT1A1 Polymorphism | Pancreatic Cancer | observational | The response rate in patients given irinotecan of ≤120 mg/m was 21.4% and progression-free survival was 8.1 months. | Source → |
| Comparing Chemotherapy Options for Pancreatic Cancer | Pancreatic Cancer | review | FOLFIRINOX had significantly better overall survival (OS) and relapse-free survival (RFS)/disease-free survival (DFS)/progression-free survival (PFS) compared to gem-cap and gem-nab/P. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.